On this page
DIRA
DIRA typically presents in the first weeks of life with severe inflammatory features including widespread pustular skin rash, bone inflammation, and internal organ involvement. It arises from pathogenic variants in IL1RN that prevent proper regulation of inflammatory signalling, leading to potentially life-threatening complications without prompt treatment.
Overview
DIRA is an exceptionally rare autoinflammatory condition that results from the body's inability to properly control inflammation. Normally, the immune system uses multiple checks and balances to prevent excessive inflammatory responses, but in DIRA this regulatory mechanism fails. The condition typically manifests within the first few weeks after birth, often appearing as a severe pustular rash alongside signs of systemic inflammation.
Because DIRA affects the fundamental pathways that control inflammation, multiple organ systems can be involved. Without appropriate treatment, the uncontrolled inflammatory state can cause serious complications affecting bones, skin, blood vessels, and internal organs. Early recognition and diagnosis are essential, as targeted therapies can effectively manage the condition and prevent long-term complications.
Symptoms & clinical features
The hallmark feature of DIRA is a widespread pustular skin eruption that typically appears within the first few weeks of life. These skin lesions often look similar to pustules seen in bacterial infections, but they arise from sterile inflammation rather than infection. The rash can be extensive and distressing, though it generally responds well to appropriate anti-inflammatory treatment.
Beyond the skin manifestations, affected infants commonly develop features of systemic inflammation including fever, irritability, and failure to thrive. Bone involvement is a prominent feature, with multifocal osteomyelitis (inflammation affecting multiple bones) causing pain, swelling, and characteristic changes visible on imaging. Some children experience widening of the ribs where they join the breastbone, creating a distinctive chest appearance. Internal organ inflammation may affect the lungs, blood vessels, and other tissues, contributing to the overall severity of untreated disease.
Video: Genetics 101
Affected organs
The skeletal system experiences particularly significant effects in DIRA, with inflammation targeting bone tissue and surrounding structures. This osteomyelitis can affect long bones, ribs, vertebrae, and other skeletal sites, potentially leading to bone lesions and abnormal bone remodelling if left untreated. The periosteum (the membrane covering bones) often becomes inflamed, causing pain and contributing to the radiological findings.
The skin is visibly affected through the characteristic pustular eruption, whilst internal inflammation can involve blood vessels (vasculitis), lungs (interstitial lung disease in some cases), and the liver. The widespread nature of inflammation reflects the fundamental role of interleukin-1 signalling throughout the body's inflammatory responses.
Risks & severity
DIRA represents a severe autoinflammatory condition that, without treatment, carries significant risks including life-threatening complications. The severity of untreated disease can be substantial, with historical reports describing fatal outcomes before effective therapies became available. The inflammatory process can cause progressive organ damage, particularly affecting bones and potentially leading to deformities or impaired growth.
With early recognition and appropriate treatment, the prognosis has improved markedly. Children who receive targeted anti-inflammatory therapy, particularly medications that block interleukin-1 signalling, typically experience dramatic improvement in symptoms and can achieve good long-term outcomes. The key determinant of severity is often the timing of diagnosis and initiation of treatment, highlighting the importance of considering DIRA when infants present with the characteristic combination of pustular rash and systemic inflammation in early life.
Genetic causes
DIRA arises from pathogenic variants in IL1RN, which provides instructions for producing interleukin-1 receptor antagonist protein. This protein plays a crucial regulatory role in the immune system by binding to interleukin-1 receptors and blocking them, thereby preventing interleukin-1 from triggering inflammatory responses. Interleukin-1 is a potent inflammatory messenger molecule, and its activity must be carefully balanced to allow appropriate immune responses whilst preventing excessive inflammation.
When IL1RN variants disrupt the production or function of interleukin-1 receptor antagonist, the body loses this essential brake on interleukin-1 signalling. The result is unopposed interleukin-1 activity, driving the severe autoinflammatory features characteristic of DIRA. Research has identified various pathogenic changes in IL1RN that can cause this deficiency, including variants that prevent protein production entirely or severely impair the antagonist's ability to block the receptor effectively.
- IL1RN interleukin 1 receptor antagonist
Inheritance pattern
DIRA follows an autosomal recessive inheritance pattern, meaning that an affected individual has inherited a pathogenic variant in IL1RN from both parents. Each parent carries one altered copy of the gene alongside one working copy, which is typically sufficient for normal interleukin-1 regulation - carriers do not usually show symptoms of DIRA.
When both parents are carriers, each pregnancy has a 25% chance of resulting in a child who inherits both pathogenic variants and develops DIRA, a 50% chance of a carrier child, and a 25% chance of a child who inherits two working copies. Siblings of an affected child have a 2-in-3 chance of being carriers if they are unaffected. Genetic counselling can help families understand these inheritance patterns and discuss options for future pregnancies, including the possibility of prenatal or preimplantation genetic diagnosis where appropriate.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of DIRA requires a combination of clinical recognition and genetic confirmation. The distinctive presentation of early-onset pustular rash, multifocal osteomyelitis, and systemic inflammation in a neonate should prompt consideration of autoinflammatory disorders including DIRA. Laboratory investigations typically show markedly elevated inflammatory markers, though these findings are non-specific.
Genetic testing provides definitive diagnosis through identification of biallelic pathogenic variants in IL1RN. In the UK, testing for autoinflammatory conditions may be accessed through clinical genetics services or specialist immunology centres. The NHS Genomic Medicine Service includes relevant testing pathways for periodic fever and autoinflammatory syndromes. Given the rarity of DIRA, consultation with specialists experienced in autoinflammatory disorders is valuable for confirming the diagnosis and guiding management.
Management & lifestyle
The cornerstone of DIRA management involves blocking interleukin-1 activity, directly addressing the underlying disease mechanism. Anakinra (prescribed according to UK-specific guidance through specialist centres) has demonstrated remarkable efficacy in treating DIRA. Many affected children show rapid improvement in symptoms following initiation of this therapy, with resolution of skin manifestations and reduction in systemic inflammation.
Care typically involves coordination between multiple specialists including immunology, rheumatology, dermatology, and clinical genetics. Regular monitoring helps assess treatment response and watch for potential complications. Because DIRA is exceptionally rare, management often benefits from consultation with national or international experts in autoinflammatory conditions. Families receive support through genetic counselling services to understand the condition's hereditary nature and implications for relatives.
UK care pathway
In the UK, children with suspected autoinflammatory conditions including DIRA are typically referred to specialist paediatric immunology or rheumatology services. The NHS Genomic Medicine Service provides access to genetic testing through appropriate clinical pathways, with panels available for periodic fever syndromes and autoinflammatory disorders. Given DIRA's rarity, tertiary referral centres with expertise in these conditions play a central role in diagnosis and management.
Families affected by DIRA can access genetic counselling through NHS clinical genetics services, which provide information about inheritance, recurrence risks, and family testing options. The multidisciplinary nature of care means that coordination between local paediatricians and specialist centres helps ensure comprehensive support for affected children and their families.
Frequently asked questions
How quickly does treatment work for DIRA?
Many children with DIRA show rapid improvement once treatment with anakinra begins, often within days to weeks. Skin manifestations typically resolve relatively quickly, whilst bone inflammation may take longer to fully settle. The dramatic response to interleukin-1 blockade can be striking and serves as further confirmation of the diagnosis.
Will my child need treatment for their entire life?
Current evidence suggests that ongoing treatment is typically necessary to maintain disease control in DIRA. Because the underlying genetic cause persists, stopping medication usually results in return of inflammatory symptoms. Long-term treatment plans are developed in consultation with specialist teams and adjusted based on individual response and needs.
Can DIRA affect my child's growth and development?
Untreated DIRA can impact growth due to chronic inflammation and its effects on bones and overall health. However, children who receive effective treatment early and maintain good disease control typically achieve normal growth and development. Regular monitoring helps ensure that growth remains on track.
What are the chances of having another child with DIRA?
If both parents are carriers of an IL1RN pathogenic variant, each pregnancy has a 25% (1-in-4) chance of resulting in a child with DIRA. Genetic counselling can discuss these risks in detail and explain options such as prenatal diagnosis or preimplantation genetic testing for families planning future pregnancies.
Is DIRA the same as other autoinflammatory conditions?
Whilst DIRA shares features with other autoinflammatory disorders, it has a distinct genetic cause and specific clinical pattern. The combination of early pustular rash and bone inflammation helps distinguish it from related conditions. Genetic testing confirms the specific diagnosis by identifying IL1RN variants.
References
- Romano M, Arici ZS, Piskin D. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the rheumatic diseases. 2022. PMID: 35623638
- Romano M, Arici ZS, Piskin D. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. Arthritis & rheumatology (Hoboken, N.J.). 2022. PMID: 35621220
- Spironolactone. 2006. PMID: 30000160
- Lachmann HJ. Periodic fever syndromes. Best practice & research. Clinical rheumatology. 2017. PMID: 29773275
- Cetin Gedik K, Arici ZS, Kul Cinar O. Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA). Paediatric drugs. 2024. PMID: 38376736
- Sá DC, Festa C Neto. Inflammasomes and dermatology. Anais brasileiros de dermatologia. 2016. PMID: 27828627
- Wen Z, Liang Y, Hao Y. Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management. Drug discovery today. 2019. PMID: 29902520
- Stern SM, Ferguson PJ. Autoinflammatory bone diseases. Rheumatic diseases clinics of North America. 2013. PMID: 24182852